natgillin/translations-raw huggingface dataset:
• plaque psoriasis (a disease causing red, scaly patches on the skin) in adults with moderate to severe disease and in patients from the age of six years with long-term severe disease;.
• psoriaze v plakih (bolezni, ki povzroča rdeče, luskaste zaplate na koži) pri odraslih z zmernim do hudim obolenjem in bolnikih, starejših od šest let, z dolgotrajno hudo boleznijo.
Enbrel treatment should be started and supervised by a specialised doctor who has experience in the diagnosis and treatment of the diseases that Enbrel is used to treat.
Zdravljenje z zdravilom Enbrel lahko uvede in nadzoruje le zdravnik specialist, ki ima izkušnje z diagnosticiranjem in zdravljenjem bolezni, za katere se uporablja zdravilo Enbrel.
Enbrel is used in patients who have not responded to or cannot receive other treatments for this disease.
Zdravilo Enbrel se uporablja pri bolnikih, ki se niso odzvali na druga zdravila za te bolezni ali pa jih ne smejo prejemati.
The active substance in Enbrel, etanercept, is a protein that has been designed to block the activity of a chemical messenger in the body called tumour necrosis factor (TNF).
Etanercept, zdravilna učinkovina v zdravilu Enbrel, je beljakovina, ki je bila zasnovana tako, da v telesu zavre aktivnost kemičnega prenašalca, imenovanega tumorje nekrotizirajoči faktor (TNF).
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Enbrel, including the appropriate precautions to be followed by healthcare professionals and patients.
V skladu s tem načrtom so bile v povzetek glavnih značilnosti tega zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
It is available as vials containing a powder that is made up into a solution for injection, and as prefilled syringes and pens containing a solution for injection.
Na voljo je v vialah, ki vsebujejo prašek za pripravo raztopine za injiciranje, ter v napolnjenih injekcijskih brizgah in peresnikih, ki vsebujejo raztopino za injiciranje.
The long term safety studies found that Enbrel could be used in polyarticular juvenile idiopathic arthritis in children from the age of two years and plaque psoriasis from the age of six years.
Študije o dolgoročni varnosti zdravila so pokazale, da se zdravilo Enbrel lahko uporablja za zdravljenje juvenilnega idiopatskega artritisa pri otrocih, starejših od dveh let, in psoriaze v plakih pri otrocih, starejših od šest let.
• moderate to severe rheumatoid arthritis (an immune system disease causing inflammation of the joints) in adults (aged 18 years or over).
• zmernega do hudega revmatoidnega artritisa (bolezni imunskega sistema, ki povzroča vnetje sklepov) pri odraslih (starih 18 let ali več).
One of these studies examined Enbrel's effects as an add-on to methotrexate in 89 patients.
V eni izmed teh študij so pri 89 bolnikih raziskovali učinke zdravila Enbrel, ki so ga uporabili kot dodatek metotreksatu.
Overall, in the studies of rheumatoid arthritis, about two-thirds of the patients receiving Enbrel had a reduction in symptoms of 20% or more after three months.
V vseh študijah revmatoidnega artritisa se je pri približno dveh tretjinah bolnikov, ki so prejemali zdravilo Enbrel, po treh mesecih jakost simptomov zmanjšala za 20 % ali več.
Patients developing a serious infection should stop Enbrel treatment.
Bolniki, pri katerih se pojavi resna okužba, morajo zdravilo Enbrel prenehati jemati.
The fifth study compared the effectiveness of Enbrel, methotrexate and a combination of both in 686 patients.
V peti študiji pa so pri 686 bolnikih primerjali učinkovitost zdravila Enbrel in učinkovitost metotreksata ter kombinacijo obeh zdravil.
Enbrel is a medicine that contains the active substance etanercept.
Enbrel je zdravilo, ki vsebuje zdravilno učinkovino etanercept.
Enbrel is used with methotrexate (a medicine that acts on the immune system) in adults with moderate or severe disease who have not responded adequately to other treatments, or on its own if methotrexate is not suitable for the patient.
Zdravilo Enbrel se uporablja skupaj z metotreksatom (zdravilom, ki učinkuje na imunski sistem) pri odraslih z zmernim do resnim obolenjem, ki so se neustrezno odzvali na druge načine zdravljenja, ali kot samostojno zdravilo, če metotreksat za bolnika ni primeren.
patients aged two to 17 years who have polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis and have not responded adequately to or cannot take methotrexate;
bolnikih, starih od dve do 17 let, ki imajo poliartritis (pozitiven ali negativen revmatoidni faktor) in razširjen oligoartritis ter se niso ustrezno odzvali na zdravljenje z metotreksatom ali pa ga ne prenašajo;
In the fifth study, Enbrel on its own or in combination with methotrexate was more effective than methotrexate alone.
V peti študiji se je izkazalo, da je bilo zdravilo Enbrel, ki so ga dajali samostojno ali v kombinaciji z metotreksatom, bolj učinkovito kot metotreksat, ki so ga bolniki jemali samostojno.
Enbrel is an anti inflammatory medicine.
Zdravilo Enbrel je protivnetno zdravilo.
For the full list of all side effects reported with Enbrel, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Enbrel, glejte navodilo za uporabo.
This messenger is found at high levels in patients with the diseases that Enbrel is used to treat.
Ta prenašalec je prisoten v velikih koncentracijah pri bolnikih z boleznimi, za zdravljenje katerih se uporablja zdravilo Enbrel.
• severe ankylosing spondylitis (a disease causing inflammation of the joints of the spine) in adults who have not responded adequately to other treatments;
• hudega ankilozirajočega spondilitisa (bolezni, ki povzroča vnetje in bolečine v sklepih hrbtenice) pri odraslih, ki se niso ustrezno odzvali na druge vrste zdravljenja;
• Severe non-radiographic axial spondyloarthritis (a chronic inflammatory disease of the spine) when there are objective signs of inflammation but no abnormalities seen on x-ray.
• hudega neradiografskega aksilnega spondilitisa (kroničnega vnetnega obolenja hrbtenice), kadar so stvarni znaki vnetja prisotni, rentgenska slika pa ne kaže nepravilnosti.
In the fourth study, Enbrel was compared with methotrexate in 632 patients who had not taken methotrexate before.
V četrti študiji so pri 632 bolnikih, ki pred tem metotreksata niso jemali, zdravilo Enbrel primerjali z metotreksatom.
How has Enbrel been studied?
Kako je bilo zdravilo Enbrel raziskano?
What is Enbrel used for?
Za kaj se zdravilo Enbrel uporablja?
This compared with around a quarter of the patients receiving placebo.
Pri bolnikih, ki so prejemali placebo, pa se je jakost simptomov zmanjšala le pri približno četrtini bolnikov.
How is Enbrel used?
Kako se zdravilo Enbrel uporablja?
Three studies compared Enbrel with placebo (a dummy treatment) in patients who had taken arthritis medicines in the past.
V treh študijah so pri bolnikih, ki so v preteklosti jemali zdravila za zdravljenje artritisa, zdravilo Enbrel primerjali s placebom (zdravilom brez zdravilne učinkovine).
adolescents aged 12 to 17 years who have psoriatic arthritis (a disease causing red, scaly patches on the skin and inflammation of the joints) and have not responded adequately to or cannot take methotrexate; adolescents aged 12 to 17 years who have enthesitis-related arthritis and have not responded adequately to or cannot take standard treatment.
mladostnikih, starih od 12 do 17 let, ki imajo psoriatični artritis (bolezen, ki povzroča rdeče, luskaste zaplate na koži in vnetje sklepov) in se niso ustrezno odzvali na zdravljenje z metotreksatom ali pa ga ne prenašajo;
What is Enbrel?
Kaj je zdravilo Enbrel?
How does Enbrel work?
Kako zdravilo Enbrel deluje?
Annex I List of the names, pharmaceutical form, strength of the medicinal products, route of administration, marketing authorisation holders in the member states
PRILOGA I SEZNAM IMEN, FARMACEVTSKA OBLIKA/E, JAKOST/I ZDRAVIL/A, POT/I UPORABE, PREDLAGATELJ/I, IMETNIK/I DOVOLJENJA ZA PROMET Z ZDRAVILOM V DRŽAVAH ČLANICAH
Chiesi Pharmaceuticals GmBH Gonzagagasse 16/6 Vienna A-1010 Austria
Madžarska Chiesi Pharmaceuticals GmBH Gonzagagasse 16/16 Vienna A-1010
Food increases the bioavailability from 80 % to 90 %.
Hrana poviša biodostopnost od 80% do 90 %.
ATCvet code: QC03DA01.
Oznaka ATC_vet: QC03DA01.
Pharmacotherapeutic group: Aldosterone antagonist.
Farmakoterapevtska skupina: Antagonist aldosterona.
(Mortality was classified as death or euthanasia due to heart failure).
( smrtnost je bila klasificirana kot pogin ali eutanazija zaradi srčne odpovedi. )
Très le Bois 22600 Loudéac France
Très le Bois 22600 Loudéac Francija
This is thought to be due to activation of feedback mechanisms without adverse clinical consequence.
To je posledica aktivacije povratnih mehanizmov brez neželenih kliničnih posledic.
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/.
Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila (European Medicines Agency, EMA) http://www.ema.europa.eu
It is therefore recommended to induce vomiting, gastric lavage (depending on risk assessment) and monitor electrolytes.
Priporočljivo je izzvati bruhanje, izprati želodec (odvisno od ocene tveganja) in monitoring elektrolitov.
Although the precise mechanism of action is not yet clearly defined, aldosterone promotes myocardial fibrosis, myocardial and vascular remodelling and endothelial dysfunction.
Čeprav natančen mehanizem delovanja še ni definiran, aldosteron pospešuje miokardialno fibrozo, miokardialno in vaskularno preoblikovanje in endotelialno disfunkcijo.
After oral administration of spironolactone to dogs, it was demonstrated that the three metabolites achieved levels from 32 % to 49 % of the administered dose.
Po peroralnem dajanju spironolaktona psom se je pokazalo, da trije metaboliti dosežejo nivoje od 32% do 49% danega odmerka.
Spironolactone may cause both induction and inhibition of cytochrome P450 enzymes and could therefore affect the metabolism of other drugs utilizing these metabolic pathways.
Spironolakton lahko povzroči indukcijo in inhibicijo citokrom P450 encimov in lahko vpliva na metabolizem drugih zdravil, ki uporabljajo te metabolne poti.
The tablet can either be mixed with a small amount of food offered prior to the main meal, or administered directly into the mouth after feeding.
Tableta se lahko primeša manjšemu delu hrane, ki se ponudi živali pred obrokom ali pa se da tableto neposredno v usta živali po hranjenju.
Ceva Santé Animale ensures that the system of pharmacovigilance, as described in Part I of the marketing authorisation application, is in place and functioning before and whilst the veterinary medicinal product is on the market.
Ceva Santé Animale zagotavlja, da je sistem farmakovigilance, kot je opisan v delu I vloge za pridobitev dovoljenja za promet, vzpostavljen in deluje, preden je zdravilo za uporabo v veterinarski medicini v prometu in ves čas trženja zdravila.
Artificial beef flavour Compressible sugar Magnesium stearate
Umetna aroma govedine Stisljiv sladkor Magnezijev stearat
Catalent Germany Schorndorf GmbH Steinbeistrasse 2
Catalent Germany Schorndorf GmbH Steinbeistrasse 2 D-73614 Schorndorf Nemčija
The tablets contain beef flavouring to improve palatability, and a study conducted in healthy dogs showed that they were voluntarily and fully consumed 75% of the time.
Tablete vsebujejo govejo aromo za izboljšanje okusnosti in študija opravljena na zdravih psih je pokazala, da v 75% psi pojedo tableto prostovoljno in v celoti.
Cardboard box containing 3 or 18 blisters of 10 tablets.
Kartonska škatla s 3 ali 18 pretisnimi omoti po 10 tablet.
Do not use after the expiry date which is stated on the carton after EXP.
Zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na ovojnini po EXP.
Plasma clearance of canrenone is 1.45±0.39 l/h/kg and 7α-thiomethyl-spironolactone is 0.89±0.44 l/h/kg.
Plazemski klirens kanrenona je 1.45±0.39 l/h/kg in 7α-tiometil-spironolaktona 0.89±0.44 l/h/kg.
The mean volumes of distribution (Vss) of 7α-thiomethyl-spironolactone and canrenone are approximately 153 litres and 177 litres, respectively.
Volumna distribucije (Vss) 7α-tiometil-spironolaktona in kanrenona sta približno 153 in 177 litrov.
In case of an accidental massive ingestion by the dog, there is no specific antidote or treatment.
V primeru, da pes nenamerno zaužije veliko količino zdravila, ne obstaja specifičen protistrup ali zdravilo.
Do not use during pregnancy and lactation, laboratory studies in species (rat, mouse, rabbit and monkey) have shown evidence of developmental toxicity.
Ne uporabite v obdobju brejosti in laktacije, laboratorijske študije na podganah, miših, kuncih in opicah so pokazale primere razvojne toksičnosti.
Administer 2 mg/kg of body weight of spironolactone once daily.
Odmerite 2 mg/kg telesne mase spironolaktona enkrat dnevno.
Do not use in dogs suffering from hypoadrenocorticism, hyperkalaemia or hyponatraemia.
Ne uporabite pri psih, ki so oboleli za hipoadenokorticizmom, hiperkaliemijo ali hiponatriemijo.
Spironolactone decreases digoxin elimination and hence raises digoxin plasma concentration.
Spironolakton zmanjša izločanje digoksina in zatorej poveča koncentracijo digoksina v plazmi.
In experimental models in dogs, it was shown that long term therapy with an aldosterone antagonist prevents progressive left ventricle dysfunction and attenuates left ventricle remodelling in dogs with chronic heart failure.
Pri eksperimentalnih vzorcih pri psih se je pokazalo, da dolgotrajna terapija z antagonisti aldosterona prepreči progresivno disfunkcijo in zmanjša preoblikovanje levega prekata pri psih s kronično srčno odpovedjo.
In a clinical study investigating the survival time in dogs with congestive heart failure, there was a 65% reduction in the relative risk of mortality at 15 months in dogs treated with spironolactone in combination with standard therapy compared to dogs treated with standard therapy alone.
Pri kliničnih testiranjih psov s kronično srčno odpovedjo, so rezultati pokazali 65% zmanjšanje rizičnosti smrtnosti pri 15 mesečnih psih, ki so bili tretirani s spironolaktonom v kombinaciji s standardno terapijo kot pri psih,ki so bili zdravljeni samo s standardno terapijo.
Lactose monohydrate Cellulose, microcrystalline Crospovidone Povidone K30
Laktoza monohidrat Celuloza, mikrokristalna Krospovidon Povidon K30
After oral administration of radiolabelled spironolactone to the dog, 70 % of the dose is recovered in faeces and 20 % in the urine.
Po peroralnem dajanju radiološko označenega spironolaktona psom so ugotovili 70 % odmerka v blatu in 20 % v urinu.
Spironolactone and its active metabolites (including 7α-thiomethyl-spironolactone and canrenone) act as specific antagonists of aldosterone, and exert their effects by binding competitively to the mineralocorticoid receptor located in the kidneys, heart and blood vessels.
Spironolakton in njegovi aktivni metaboliti (vključno z 7α-tiometil-spironolaktonom in kanrenonom) delujejo kot specifični antagonisti aldosterona, ki svoje učinke kažejo s kompetitivno vezavo na mineralokortikoidne receptorje v ledvicah, srcu in krvnih žilah.
Do not use in conjunction with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in dogs with renal insufficiency (kidney impairment/dysfunction).
Ne uporabite skupaj z nesteroidnimi protivnetnimi zdravili (NSAID) pri psih z insuficienco ledvic (ledvično okvaro/disfunkcijo).
Partially used tablets should be stored in the original blister and used within 7 days.
Delno uporabljene tablete shranjujte v originalnem pretisnem omotu in jih uporabite v 7 dneh.
There may be a dose related hypertrophy of the adrenal zona glomerulosa at high dose rates.
Pri visokih odmerkih se lahko pojavi od odmerka odvisna hipertrofija adrenalne zone glomerulose.
Unlike in humans, an increased incidence of hyperkalaemia was not observed in clinical trials performed in dogs with this combination.
Za razliko od ljudi, se pogostost povečane hiperkalemije ni pokazala pri kliničnih testiranjih pri psih v omenjeni kombinaciji.
Steady-state conditions are reached by day 2.
Stalno stanje je doseženo v 2 dneh.
Spironolactone is rapidly and completely metabolised by the liver into its active metabolites, 7αthiomethyl-spironolactone and canrenone, which are the primary metabolites in the dog.
Spironolakton se hitro in v celoti metabolizira v jetrih v aktivna metabolita, 7α-tiometil-spironolakton in kanrenon, ki sta primarna metabolita pri psih.
Polyamide/aluminium/polyvinyl chloride//aluminium blisters containing 10 tablets.
Poliamid/aluminij/polivinil klorid//aluminij pretisni omot z 10 tabletami.
Spironolactone is a natriuretic drug (historically described as a soft diuretic).
Spironolakton je natriuretično zdravilo (poznan kot blag diuretik).
A reversible prostatic atrophy (reduction in size) is often observed in entire male dogs.
Reverzibilna atrofija prostate ( redukcija v velikosti ) je pogosto opažena pri nekastriranih samcih.
Furosemide and pimobendan have been used together with Spironolactone Ceva in dogs with heart failure without any clinical evidence of adverse reactions.
Furosemid in pimobendan sta bila uporabljena skupaj s Prilaktonom pri psih s srčno odpovedjo brez pojava kliničnih znakov neželenih učinkov.
Mean Cmax of 382 μg/l and 94 μg/l are achieved for the primary metabolites, 7αthiomethyl-spironolactone and canrenone, after 2 and 4 hours, respectively.
Najvišjo Cmax 382 μg/l in 94 μg/l dosežeta primarna metabolita, 7α-tiometil-spironolakton in kanrenon, po 2 in 4 urah.
Do not use during pregnancy or lactation.
Ne uporabite v obdobju brejostji in laktacije.
The renal effects of spironolactone and its metabolites lead to a decrease in extracellular volume and consequently in a decrease of cardiac preload and left atrial pressure.
Učinki spironolaktona in njegovih metabolitov v ledvicah vodijo do zmanjšanja ekstracelularnega volumna in posledično do zmanjšanega pritoka v srce in pritiska v levem atriju.
Dogs treated concomitantly with spironolactone and NSAIDs should be correctly hydrated.
Psi, ki so stalno zdravljeni z spironolaktoni in NSAID (nesteroidno protivnetno zdravilo) morajo biti ustrezno hidrirani.
White HDPE bottle containing 30 tablets with a white polypropylene child-resistant tamper-evident screw cap fitted with a desiccant insert, packaged in a cardboard box.
Bel HDPE vsebnik, ki vsebuje 30 tablet, z belim polipropilenskim, za otroke varnim, pokrovčkom, opremljen s sušilnim vložkom, pakiran v kartonski škatli.
Sodium laurilsulfate Microcrystalline cellulose Povidone
Natrijev lavrilsulfat Mikrokristakna celuloza Povidon
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
ODMERKI ZA POSAMEZNE ŽIVALSKE VRSTE TER POT(I) IN NAČIN UPORABE ZDRAVILA Peroralna uporaba.
30 tablets 180 tablets
180 tablet
Use within 2 months after first opening the bottle.
2 meseca po prvem odprtju vsebnika.
In the kidney, spironolactone inhibits the aldosterone-induced sodium retention leading to increase in sodium and subsequently water excretion, and potassium retention.
V ledvicah spironolakton inhibira aldosteronsko inducirano zadrževanje natrija, kar vodi k zvečanemu izločanju natrija in posledično izločanju vode in zadrževanju kalija.
A slight increase in aldosterone blood levels may be observed in animals on treatment.
Pri zdravljenih živalih se lahko opazi rahlo povišanje nivoja krvnega aldosterona.
Concomitant administration of spironolactone with ACE-inhibitors and other potassium-sparing drugs (as angiotensin receptor blockers, ß-blockers, calcium channels blockers, etc) may potentially lead to hyperkalaemia (see section "Special precautions for use in animals").
Hkratno dajanje spironolaktona z inhibitorji ACE in drugimi s kalijem revnimi zdravili (kot blokatorji angiotenzinskih receptorjev, ß-blokatorji, blokatorji kalcijevih kanalov, itd..) lahko privede do hiperkaliemije (glej poglavje "Posebni previdnostni ukrepi za uporabo pri živalih").
The administration of either deoxycorticosterone or NSAIDs with spironolactone may lead to a moderate reduction of the natriuretic effects (reduction of urinary sodium excretion) of spironolactone.
Aplikacija deoxykortikosteronov ali NSAID(nesteroidno protivnetno zdravilo) s spironolaktonom lahko povzroči zmerno znižanje natridiuretičnega učinka spironolaktona (zmanjšano izločanje natrija z urinom).
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
6.6 Posebni varnostni ukrepi za odstranjevanje neporabljenega zdravila ali odpadnih snovi Vsako neporabljeno zdravilo za uporabo v veterinarski medicini ali odpadne snovi, ki nastanejo iz teh zdravil, je treba odstraniti v skladu z lokalnimi predpisi..
Concomitant administration of spironolactone with ACE-inhibitors and other potassium-sparing drugs (as angiotensin receptor blockers, ß-blockers, calcium channels blockers…etc) may potentially lead to hyperkalaemia (see section 4.5).
Hkratna aplikacija spironolaktona z inhibitorji ACE in drugimi s kalijem revnimi zdravili (kot blokatorji angiotenzinskih receptorjev, ß-blokatorji, blokatorji kalcijevih kanalov itd) lahko privede do hiperkaliemije (glej poglavje 4.5).
As the therapeutic index for digoxin is very narrow, it is advisable to monitor closely dogs receiving both digoxin and spironolactone.
Ker je terapevtski indeks digoksina zelo ozek, je priporočljivo spremljati stanje živali, ki je zdravljenaz digoksinom in spironolaktonom.
As spironolactone has an antiandrogenic effect, it is not recommended to administer the veterinary medicinal product to growing dogs.
Ker ima spironolakton antiandrogen učinek, ni priporočljiva uporaba zdravila za uporabo v veterinarski medicini pri rastočih psih.
The veterinary medicinal product should be administered with food.
Zdravilo za uporabo v veterinarski medicini se da primešano v hrano.
Bottle containing 30 tablets packed in a cardboard box.
Velikost pakiranja: Vsebnik s 30 tabletami v kartonski škatli.
SPECIAL WARNING(S), IF NECESSARY
POSEBNO(A) OPOZORILO(A), ČE JE/SO POTREBNO(A) Pred uporabo preberite navodilo za uporabo
MANUFACTURER'S BATCH NUMBER
IZDELOVALČEVA ŠTEVILKA SERIJE Lot :
METHOD AND ROUTE(S) OF ADMINISTRATION
NAČIN IN POT(I) UPORABE Peroralna uporaba
May cause skin sensitisation: people with known hypersensitivity to spironolactone should avoid contact with the veterinary medicinal product.
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo Lahko povzroča kožne reakcije: osebe z znano preobčutljivostjo na spironolakton naj se izogibajo stiku z zdravilom za uporabo v veterinarski medicini.
Cardboard box of 1 bottle of 30 tablets
PODATKI NA ZUNANJI OVOJNINI Kartonasta škatla z 1 vsebnikom s 30 tabletami
A reversible prostatic atrophy is often observed in entire male dogs.
Reverzibilna atrofija prostate je pogosto opažena pri nekastriranih samcih.
Kidney function and serum potassium levels should be evaluated before initiating combined treatment with spironolactone and Angiotensin Converting Enzyme (ACE) inhibitors.
Posebni previdnostni ukrepi za uporabo pri živalih Pred začetkom kombiniranega zdravljenja s spironolaktonom in inhibitorji angiotenzin konvertirajočega encima (ACE) je treba oceniti ledvično funkcijo in nivo serumskega kalija.
However, in dogs with renal impairment regular monitoring of renal function and serum potassium levels is recommended as there may be an increased risk of hyperkalaemia.
Vendar pa pri psih z ledvično oslabelostjo obstaja tveganje hiperkaliemije in se zato priporoča redni monitoring ledvične funkcije in nivoja serumskega kalija.
Symptomatic treatment, e.g., fluid therapy, should be provided.
Priporočljiva je simptomatska terapija kot so infuzije.
Blister - 10 mg tablets, 40 mg tablets and 80 mg tablets
Pretisni omot - 10 mg tablete, 40 mg tablete in 80 mg tablete